ArticleOTO open
Intranasal Oxymetazoline and Xylometazoline Use in Patients With Deviated Nasal Septum: A Cross-Sectional Telephone Survey.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the pattern of oxymetazoline and xylometazoline (OXM) use in patients with deviated nasal septum (DNS). Study design: A retrospective Computer-Assisted Telephone Interviewing survey. Setting: Patients who underwent septoplasty in University Clinical Hospital in Opole, Poland. Methods: A retrospective Computer-Assisted Telephone Interviewing (CATI) survey was conducted among patients who underwent septoplasty between 2018 and 2024. The questionnaire included inquiries about the frequency of OXM use, awareness of the consequences of long-term OXM application, and alternative treatment options, all prior to septoplasty. Results: The study was conducted on 159 of 305 (52.1%) patients identified in the hospital database. Approximately one-third of respondents (55 of 159, 34.6%) denied using OXM, about one-third had used OXM for no more than 7 days (52 of 159, 32.7%), and the remaining one-third (52 of 159, 32.7%) admitted to OXM overuse. Lack of awareness of the consequences of chronic OXM use was associated with a 6.5-fold increased risk of addiction (OR = 6.5, 95% CI: 1.2-33.6, Conclusions: DNS may increase the risk of OXM dependence; however, further controlled studies are needed. Increasing awareness about the risks of OXM overuse substantially reduces this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.